Login
Companies $CMPS
$8.35 +$0.08 (0.95%) After hours
COMPASS Pathways plc logo

COMPASS Pathways plc

compasspathways.com

What Do They Do?

Develops an investigational psilocybin treatment for people with serious mental health conditions, initially treatment-resistant depression, with PTSD also in development.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +93% (Loss)
vs −$137.7M in Q3 FY2025

A narrower development focus The older report describes an anorexia program and research into additional compounds; the latest report focuses its pipeline on treatment-resistant depression and PTSD.

Who Do They Compete With?

Competes with Janssen, Supernus Pharmaceuticals, Neurocrine Biosciences, GH Research, Beckley Psytech, Usona Institute, and Helus Pharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support